Annuncio • Jul 27
Neonc Technologies Holdings, Inc. Announces Appointment of Nasim Shomali to Board of Directors, Effective July 1, 2026 NeOnc Technologies Holdings, Inc. announced the appointment of Nasim Shomali to its Board of Directors, effective July 1, 2026. Ms. Shomali brings more than a decade of experience advising large, complex organizations on corporate strategy, operating models, financial planning, and organizational transformation, grounded in formal training in biomedical engineering and finance. Most recently, she served as a Strategy Executive at Accenture, where she advised Fortune-100 and multinational enterprises across the life sciences, technology, and energy sectors. Her work spanned corporate strategy development, financial and pro-forma modeling, market sizing, operating-model design, and C-suite and Board-level advisory, including engagements in the medical technology sector focused on product lifecycle economics and next-generation product design. Earlier in her career, Ms. Shomali gained private equity experience at Maybrook Capital Partners, where she led commercial and financial diligence and developed investment-grade analyses, and she began her career in an engineering role at InBios International, Inc., a life sciences company, where she worked on manufacturing throughput and product profitability initiatives. Ms. Shomali holds a Master of Business Administration in Finance from the UCLA Anderson School of Management and completed an executive program in sustainable leadership development at the Yale School of Management. She earned a Bachelor of Science in Bioengineering and a Bachelor of Arts in Mathematics from the University of Washington. New Risk • Jul 16
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$95.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$13m). Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$14m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$95.4m market cap). Annuncio • Jul 16
NeOnc Technologies Holdings, Inc. Receives FDA Written Feedback On NEO212 CMC Development And Capsule-To-Tablet Transition NeOnc Technologies Holdings, Inc. has received written feedback from the U.S. Food and Drug Administration regarding the chemistry, manufacturing and controls development program for NEO212, the Company’s novel temozolomide-perillyl alcohol conjugate. The written feedback was provided in advance of a Type B End-of-Phase 1 meeting scheduled for July 9, 2026. FDA’s preliminary comments expressly provided NeOnc the option to cancel the meeting if the written responses were sufficiently clear, in which case the written responses would constitute the official record of the meeting. After reviewing the detailed responses, the Company determined that an additional meeting discussion was not required at this stage and canceled the July 9 meeting. Key elements of the FDA’s written feedback include: FDA stated that NeOnc’s proposed approach to CMC development appears reasonable, while identifying additional comparative assessments that may be required if the drug-substance manufacturing process or physical characteristics change during development. FDA stated that the general drug-product development plan may proceed in parallel with the Company’s planned late-stage clinical program, subject to the development and submission of appropriate supporting data. FDA indicated that a staged stability program supporting clinical development, followed by registration stability studies, is a commonly accepted approach. FDA advised that the transition from the current capsule formulation to a tablet formulation should be supported by an in vivo relative bioavailability study. FDA identified CMC work to be completed before representative tablet material is used in a confirmatory clinical phase, including finalization of the tablet formulation and manufacturing process, manufacture of at least one GMP batch, establishment of appropriate in-process controls, solid-state and particle-size characterization, and development of an appropriate dissolution method. NeOnc is incorporating the FDA’s feedback into its NEO212 development plan and is evaluating the associated study design, manufacturing activities, timelines and costs. The Company expects to provide an updated development plan after completing this assessment. The FDA feedback relates principally to the CMC development of NEO212 and the capsule-to-tablet transition. The written responses do not constitute FDA approval of NEO212 or agreement on the design or adequacy of any future registrational clinical trial. Any future clinical study remains subject to applicable regulatory requirements and continued FDA review. NEO212 is a novel covalently conjugated compound combining the chemotherapeutic agent temozolomide with perillyl alcohol. NeOnc is developing NEO212 as a potential treatment for malignant brain tumors and other central nervous system cancers. NeOnc’s NEO100 and NEO212 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast Track and Investigational New Drug status. The Company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. Annuncio • Jul 03
NeOnc Technologies Holdings, Inc. Announces Board and Committee Changes NeOnc Technologies Holdings, Inc. announced that Ming-Fu (Alan) Chiang, M.D., Ph.D., MBA, a Class II director, resigned as a member of the Company's Board of Directors, effective June 27, 2026. In connection with his resignation, Dr. Chiang also resigned from the Company's Scientific Advisory Board. Dr. Chiang's resignation was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies, or practices. The company announced that on July 1, 2026, the Board of the Company elected Nasim Shomali as a director of the Company, effective July 1, 2026, to serve as a Class II director until the Company's 2027 annual meeting of stockholders. From April 2013 to April 2026, Ms. Shomali served as a Strategy Executive at Accenture. In this capacity, she advised senior executives at Fortune 20 companies on enterprise strategy, operating-model development, and large-scale transformation initiatives. Her work included leading corporate strategy programs, supporting product redesign and new-product introduction, guiding market-expansion strategies, and developing automation and efficiency roadmaps across global business units. She also managed and expanded Accenture's U.S. Software, Platform, and Technology sustainability portfolio. Ms. Shomali earned her M.B.A., with a concentration in finance, from the UCLA Anderson School of Management. She holds dual bachelor's degrees in Bioengineering and Mathematics from the University of Washington and completed the Sustainable Leadership Development Executive Program at the Yale School of Management. Annuncio • Jun 26
NeOnc Technologies Holdings, Inc. announced that it has received $5.00004 million in funding On June 25, 2026, the company has received the funding of $5,000,000. The company pays the sales commission of $500,000. The transaction is closed pursuant to Regulation D. Annuncio • Jun 25
NeOnc Technologies Holdings, Inc., Annual General Meeting, Aug 14, 2026 NeOnc Technologies Holdings, Inc., Annual General Meeting, Aug 14, 2026. Annuncio • Jun 23
NeOnc Technologies Holdings, Inc. Receives UAE IND Approval For NEO100, Expanding Global Development Ahead Of Anticipated Phase 2 Data Milestone NeOnc Technologies Holdings, Inc. announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company’s lead candidate, an intranasally administered formulation of purified perillyl alcohol designed for non-invasive nose-to-brain delivery. The authorization covers the Company’s NEO100-01, NEO100-02, and NEO100-03 protocols across Phase 1, Phase 1b, and Phase 2 studies in adults, together with pediatric studies authorized for Phase 1 and Phase 1b pending further protocol review. The authorized indication is progressive or recurrent Grade III or IV gliomas. The breadth of the UAE authorization, spanning three protocols and adult studies from Phase 1 through Phase 2 alongside a defined pediatric pathway, is intended to allow NeOnc to advance multiple stages of clinical development in parallel. The authorization follows the DOH’s recent IND clearance for the Company’s NEO212 program, announced in June 2026, and extends NeOnc’s clinical development footprint in the UAE across both of its lead platforms, the intranasal delivery platform represented by NEO100 and the drug-conjugation platform represented by NEO212. In the United States, NEO100 has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, and its lead clinical study, the NEO100-01 Phase 2a trial in recurrent IDH1-mutant high-grade glioma, is fully enrolled. The Company expects to report top-line data from the fully enrolled NEO100-01 Phase 2a trial by the end of July 2026, representing what NeOnc believes may be one of the most important clinical milestones in the Company’s history. NEO100 uses intranasal delivery to reach the brain directly, a practical route that circumvents the blood-brain barrier without surgery or systemic chemotherapy. Because it is non-invasive, this approach can enable studies in difficult groups, including children with high-grade gliomas that have few options today. An authorization spanning Phase 1 through Phase 2 with a pediatric pathway lets the company pursue that work where it is needed most. The upcoming Phase 2a readout represents the first controlled evaluation of NEO100 in recurrent IDH1-mutant high-grade glioma following encouraging earlier clinical observations. High-grade gliomas, including WHO Grade III and IV disease, are among the most aggressive brain cancers, with limited treatment options after recurrence. The Company expects to work with healthcare institutions, investigators, and regulatory authorities in the UAE as clinical development activities advance. The UAE authorization further positions NeOnc to rapidly expand clinical development activities internationally as the Company prepares for multiple anticipated regulatory and clinical milestones throughout the second half of 2026. Annuncio • Jun 19
Neonc Technologies Holdings Receives Abu Dhabi Ind Authorization for Neo212 and Completes Phase 1 Dose-Escalation Study NeOnc Technologies Holdings received Investigational New Drug (IND) authorization from the Department of Health – Abu Dhabi for NEO212, an oral perillyl alcohol-temozolomide conjugate being developed for aggressive brain tumors, including glioblastoma. The authorization marks the first international regulatory clearance for NEO212 and follows completion of the company's Phase 1 dose-escalation study, which established 610 mg as the recommended Phase 2 dose. The approval provides NeOnc with an additional clinical development pathway outside the United States. NeOnc continues active discussions with the U.S. Food and Drug Administration regarding a potential registrational strategy and future development plans. NeOnc's platform is specifically designed to overcome the blood-brain barrier through proprietary delivery technologies intended to improve therapeutic access to the brain while potentially reducing systemic toxicity. Among NeOnc's most closely watched programs is NEO100, a patented intranasal formulation of proprietary perillyl alcohol designed for direct nose-to-brain delivery. The program has completed enrollment in its Phase 2a study evaluating recurrent IDH1-mutant high-grade glioma and related brain cancers. Previous updates highlighted encouraging clinical observations, including tumor remission reported in approximately 24% of recurrent glioblastoma patients treated with NEO100. NEO212 combines NEO100 with temozolomide, the current standard chemotherapy commonly used in glioblastoma treatment. Preclinical and early-stage findings suggest NEO212 may achieve approximately three times greater brain exposure than temozolomide alone. Following completion of the Phase 1 dose-escalation study and the selection of the recommended Phase 2 dose, NeOnc is preparing for a Type B End-of-Phase 1 meeting with the FDA to discuss future development plans and potential Phase 2 pathways. The recent Abu Dhabi IND authorization provides an additional opportunity to expand clinical evaluation internationally while potentially generating additional data that could support future regulatory discussions. Annuncio • Jun 17
NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND NeOnc Technologies Holdings announced that the Department of Health – Abu Dhabi granted Investigational New Drug authorization for NEO212, the company's oral perillyl alcohol-temozolomide conjugate being developed for aggressive brain tumors. The approval represents the first international regulatory clearance for NEO212 following completion of the Phase 1 dose-escalation study, which established 610 mg as the recommended Phase 2 dose. The authorization creates an additional clinical development pathway outside the United States as the company continues discussions with the U.S. Food and Drug Administration regarding a potential registrational strategy. One of the company's most closely watched programs is NEO100, a patented intranasal composition of a proprietary synthesis perillyl alcohol designed for direct nose-to-brain delivery. The program has now achieved full enrollment in its Phase 2a study evaluating recurrent IDH1-mutant high-grade glioma and related brain cancers. Recent updates have highlighted encouraging clinical observations, including tumor remission reported in approximately 24% of recurrent glioblastoma patients treated with NEO100. Investors are now looking toward anticipated interim and top-line data expected later in 2026. Analysts have identified NEO100 as one of NeOnc's primary near-term catalysts, citing the program's differentiated delivery approach and the significant unmet need that continues to exist throughout neuro-oncology. Beyond NEO100, NeOnc has also continued making progress with NEO212, an oral bioconjugate combining NEO100 and temozolomide. The company recently completed the Phase 1 dose-escalation portion of the study and established 610 mg as the recommended Phase 2 dose. According to analyst commentary, prior data suggest NEO212 may achieve approximately three times greater brain exposure compared with temozolomide alone. The company is now preparing for an FDA Type B End-of-Phase 1 meeting to align on Phase 2 development plans and potential next steps. Analysts covering the company have specifically highlighted the broader blood-brain-barrier bypassing platform as a potentially important differentiator, with NEO100 representing a more advanced clinical opportunity while NEO212 provides an additional development pathway targeting aggressive brain cancers. Annuncio • Jun 16
NeOnc Technologies Holdings, Inc Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development NeOnc Technologies Holdings, Inc. announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212, the Company’s orally administered perillyl alcohol-temozolomide carbamate conjugate being developed for patients with aggressive brain tumors. The authorization marks the first international regulatory clearance for NEO212 following completion of Phase 1 clinical evaluation and represents a significant step toward expanding the program into multiple global markets. NEO212 recently completed the Phase 1 dose-escalation portion of its Phase 1/2 study, which established 610 mg as the recommended Phase 2 dose. In that study, the Company reported encouraging early signs of clinical activity, including potential durable disease stabilization, in heavily pretreated patients with recurrent glioblastoma (GBM) and brain metastases. NeOnc expects this authorization to support the advancement of NEO212 into Phase 2 clinical development while continuing discussions with the U.S. Food and Drug Administration regarding the design of a potential registrational pathway. The Company believes parallel regulatory and clinical activities across multiple jurisdictions may accelerate the overall development strategy for NEO212. Under the terms of the DOH authorization, NeOnc must satisfy a number of conditions before patient enrollment in the UAE, including separate approval from the DOH Institutional Review Board (IRB) and amendments to the study protocol, investigator’s brochure, and product labeling. The DOH clearance applies to the conduct of clinical research and does not constitute marketing authorization. The Company has also submitted applications to the Department of Health – Abu Dhabi for its NEO100 clinical programs, including NEO100-01, NEO100-02, and NEO100-03, and is currently awaiting regulatory decisions. If approved, these programs would further expand NeOnc’s clinical development footprint in the UAE and support the Company’s strategy of advancing multiple brain cancer and neurological therapeutic programs in parallel across key international markets. Glioblastoma remains one of the deadliest forms of cancer, with limited treatment options and poor long-term survival outcomes. NEO212 is designed to combine the chemotherapeutic temozolomide with perillyl alcohol in a single orally administered conjugate intended to improve delivery across the blood-brain barrier. The Company expects to work with healthcare institutions, investigators, and regulatory authorities in the UAE as clinical development activities advance. Board Change • May 20
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. President, CEO, Executive Chairman & Secretary Amir Heshmatpour is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annuncio • Apr 12
NeOnc Technologies Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. NeOnc Technologies Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Annuncio • Mar 13
NeOnc Technologies Holdings, Inc. Appoints David Choi as Chief Accounting Officer NeOnc Technologies Holdings, Inc. has appointed David Choi as Chief Accounting Officer . In this role, Mr. Choi is responsible for overseeing the Company’s accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations. Mr. Choi has more than a decade of experience in accounting, financial reporting, and internal controls for both public and private companies. Prior to joining NeOnc, Mr. Choi was a Director at Blythe Global Advisors, where he advised companies across multiple industries on technical accounting matters, SEC reporting, and SOX compliance. He led engagements involving financial reporting transformation, internal control design and implementation, and accounting for complex transactions including equity instruments, debt financing, and business combinations. Earlier in his career, Mr. Choi held positions at Grant Thornton and Ernst & Young, where he provided assurance and advisory services to public and private companies. His experience includes financial statement audits, technical accounting advisory, and SOX readiness and compliance for internal controls over financial reporting. Mr. Choi is a Certified Public Accountant (CPA). He holds a Master of Professional Accountancy and a Bachelor of Arts in Business Economics with a minor in Accounting from the University of California, Irvine. Annuncio • Mar 06
NeOnc Technologies Holdings Reports Phase 1 Dose-Escalation Results and Determines Recommended Phase 2 Dose for Oral Neo212 NeOnc Technologies Holdings, Inc. has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second Dose-Limiting Toxicity. In accordance with protocol-defined stopping rules, dose escalation has been halted, no further patients will be enrolled at 810 mg, and the Recommended Phase 2 Dose (RP2D) has been set at 610 mg (Cohort 4). For the Phase 2a metastasis cohort, the starting dose will be 400 mg (Cohort 3). Notably, although Phase 1 was mainly designed to assess safety, tolerability, and identify the MTD, promising signs of clinical efficacy appeared during this phase of the study. These efficacy signs—including indications of lasting disease control in heavily pretreated patients with recurrent GBM and brain metastases—were observed within the dose-escalation groups. The emergence of measurable anti-tumor activity in Phase 1 offers early clinical confirmation of NEO212’s therapeutic potential and supports the Company’s progress into the Phase 2 segment of the trial. The transition into Phase 2 will focus on further assessing efficacy at the RP2D in specific expansion cohorts, aiming to generate strong clinical data to support potential accelerated development pathways in recurrent CNS cancers. This represents the first clinical readout of NeOnc’s bioconjugated temozolomide (TMZ) platform in an oral formulation, demonstrating NeOnc’s drug-engineering capabilities beyond its established intranasal delivery platform. The data validate the Company’s ability to optimize CNS penetration and therapeutic exposure across both intranasal and oral modalities. NeOnc intends to request a Type B (End-of-Phase 1) FDA meeting to review safety, PK/PD, preliminary efficacy, RP2D justification, Phase 2 design modifications, and a potential Accelerated Approval pathway. Supporting regulatory materials, including MedWatch Form FDA 3500A and Form FDA 1571, have been submitted via eCTD, ensuring regulatory transparency and alignment as the program transitions into Phase 2 development. NEO212 is specifically designed to overcome a key biological limitation of TMZ: MGMT-mediated resistance. Preclinical studies have shown that NEO212 effectively inactivates and promotes the degradation of O6-methylguanine-DNA methyltransferase (MGMT), a crucial DNA repair enzyme that causes TMZ resistance. Standard TMZ treatment does not significantly lower MGMT levels and remains vulnerable to MGMT-driven DNA repair in brain tumors. This mechanistic difference may be especially important for TMZ-resistant and MGMT-high recurrent glioblastoma patients, offering a strong biological reason to advance NEO212 into Phase 2 development in the post-TMZ setting. NEO212 is NeOnc’s first oral chemical conjugated chemotherapy drug, uniquely combining Temozolomide (TMZ), the current standard of care for glioblastoma and other brain cancers (marketed as Temodar®), with NEO100 (a proprietary form of perillyl alcohol (POH), which is owned and patented by NeOnc). This proprietary conjugation is designed to overcome the limitations of TMZ, including resistance and limited efficacy, by enhancing blood-brain barrier penetration and antitumor activity. Annuncio • Jan 30
NeOnc Technologies Holdings, Inc. announced that it expects to receive $15.999998 million in funding NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement to issue 2,222,222 shares at a price of $7.20 per share and five-year warrants to purchase up to 2,222,222 shares of Common Stock at a per share exercise price of $9.00 for gross proceeds of $15,999,998.4 on January 29, 2026. Annuncio • Dec 16
NeOnc Technologies Holdings, Inc. Reports Updated Clinical Results NeOnc Technologies Holdings, Inc. announced updated clinical results from its ongoing Phase 1/2a and compassionate-use experience evaluating intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma. Since the Company's prior announcement and 8K event on November 12, 2025, an additional patient has achieved both durable long-term survival and radiographic remission, further strengthening the clinical signal observed with intranasal NEO100. With this update, the expanded clinical cohort now includes 25 patients, reinforcing the reproducibility and durability of treatment benefit. Updated results demonstrate that treatment with intranasally delivered NEO100 has resulted in significant radiographic remission in 6 of 25 patients (24%), representing 3X increase over the 8% response rates typically reported with salvage therapies in recurrent high-grade gliomas. Additionally, 44% of patients achieved six-month progression-free survival (PFS-6), exceeding historical benchmarks of 21-31% for IDH1-mutant recurrent high-grade glioma. Importantly, 9 of 25 patients (36%) remain alive 18 months following initiation of NEO100, providing further evidence of meaningful long-term survival in this heavily pretreated population. No significant toxicity has been observed with intranasal administration of NEO100, even with prolonged and chronic dosing. Annuncio • Dec 02
NeOnc Technologies Holdings, Inc. Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Existing Effective Neo100 in Treating Primary and Metastatic Brain Tumors NeOnc Technologies Holdings, Inc. announced newly published preclinical findings from a research collaboration at the University of Southern California (USC). The study, now available on bioRxiv, demonstrates that ultrasound further enhances and amplifies NEO100's therapeutic potency, driving strong antitumor effects across multiple primary and metastatic brain tumor types. Utilizing an AI-driven, 3D-bioprinted New Approach Methodology (NAM), researchers at USC, led by Dr. Josheman--Ass Associate Professor of Neurological Surgery and Chief Clinical Officer of NTHI--identified NEO100 as a leading sonodynamic therapy agent. This NAM platform--built on NTHI-patented rapid magnetic 3D bioprinting technology (US Patent 11,788,057)--facilitates the rapid generation of physiologically relevant patient-derived tumor organoids within hours, rather than the weeks typically required by conventional methods, thereby significantly accelerating biomedical research and aligning with NIH objectives to minimize animal testing. An AI-driven positive-unlabeled neural network, trained on over 200 molecular descriptors, was employed to predict compounds most likely to respond to focused ultrasound, penetrate the blood-brain barrier, and exhibit potent sonodynamic therapeutic activity. Throughout this extensive AI screening initiative, the platform consistently identified NEO100 as a leading predicted sonosensitizer. Validation studies on rapidly bioprinted tumor spheroids--including glioblastoma, pediatric medulloblastoma, high-grade meningioma, and breast- and lung-to-brain metastases-- demonstrated that NEO100 displayed markedly enhanced tumor-killing activity when combined with focused ultrasound parameters. Together, these results support moving NEO100 combined with focused ultrasound into future clinical trials for a wide range of primary and metastatic brain tumors. Annuncio • Nov 17
NeOnc Technologies Holdings, Inc. Announces Board Changes, Effective November 12, 2025 As previously reported on NeOnc Technologies Holdings, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 22, 2025, Dr. Ming-Fu Chiang resigned from the Board of Directors (the Board") of the Company and Ishwar K. Puri was appointed to the Board. After his appointment, the University of Southern California had objected to Mr. Puri's appointment to the Board and indicated that Mr. Puri must resign from the Board. Mr. Puri tendered his resignation to the Company on November 12, 2025. On November 12, 2025, the Board elected Dr. Ming-Fu Chiang as a director of the Company, effective immediately, to serve until the Company's 2026 annual meeting of stockholders. Dr. Ming-Fu Chiang served on the Board from March 2025 to August 2025. Dr. Chiang was a neurosurgeon and the former Vice-Director of the Department of Surgery and former Chairman of Neurosurgery at Mackay Memorial Hospital in Taipei, Taiwan from August 1991 to June 2020. Since July 2020, he is a practicing neurosurgeon at Chung-Shan Hospital and Taiwan Adventist Hospital in Taipei, Taiwan. Dr. Chiang has a Ph.D. in neuro-oncology from Free University of Berlin, Germany, and his EMBA (Executive Management Business & Administration) from National Taiwan University. Dr. Chiang has also previously served as the CEO of NeuCen Biomedical, Inc. and Orio Biotech Inc. Annuncio • Nov 16
NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High-Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026) NeOnc Technologies Holdings, Inc. announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial. The trial is evaluating the company's lead therapeutic candidate, NEO100, for the treatment of recurrent isocitrate dehydrogenase 1 (IDH1)-mutant high-grade glioma (WHO Grade III and IV). The Company anticipates reporting preliminary data from this fully enrolled cohort in approximately six months, during the second quarter of 2026. Annuncio • Nov 13
NeOnc Technologies Holding Inc Reports Updated Results of Clinical Trials Provide Evidence Supporting Significant Radiographic Response and Potential Long-Term Survival in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100 NeOnc Technologies Holdings, Inc. announced updated clinical results from its current Phase 1/2a and compassionate care studies involving a cohort of 24 patients with recurrent WHO Grade III/IV isocitrate dehydrogenase 1 (IDH1)-mutant astrocytoma treated with its investigational intranasal agent, NEO100. Clinical results provided support that treatment with intranasally delivered NEO100 resulted in a significant radiographic response, confirmed by contrast-enhanced and perfusion MRI, in 5 of 24 patients (21%)--a rate that clearly exceeds the <8% response typically observed with salvage therapies for recurrent gliomas. Additionally, results indicated that 44% of patients in this Phase 2a study achieved six-month progression-free survival (PFS-6), surpassing the 21-31% benchmark reported in historical datasets for IDH1-mutant recurrent high-grade gliomas. Furthermore, 8 of 24 patients (33%) remained alive 18 months after initiation of NEO100, demonstrating long term survival. In addition, no significant toxicity was reported with intranasal administration of NEO100, even with prolonged, chronic intranasal administration, underscoring its potential utility as a therapeutic option for this patient population. Patients received intranasal administration ofEO100, and results were assessed using Response Assessment in Neuro-Oncology (RANO) criteria. Collectively, these findings indicate that NEO100 could represent a first-in-class, CNS-penetrant metabolic therapy potentially inducing significant radiographic response and extending survival in patients with recurrent Grade III/IV IDH1-Mutant Astrocytoma, thereby potentially offering a major advancement over past approaches predominantly limited to palliative care. Annuncio • Nov 05
NeOnc Technologies Holdings, Inc. Announces CEO Changes NeOnc Technologies Holdings, Inc. announced that its Board of Directors has appointed Amir Heshmatpour as Chief Executive Officer. Mr. Heshmatpour, who was appointed President in April, will assume the CEO role effective immediately, continuing to serve as Executive Chairman of the Board. Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Directors, ensuring his continued leadership over NeOnc's innovative scientific strategy and clinical development. Since being appointed President, Mr. Heshmatpour has been instrumental in securing a series of transformative achievements for NeOnc. These include the finalization of a $50 million strategic partnership with Quazar Investment, the establishment of NuroMENA as a UAE-based subsidiary under the Executive Chairmanship of His Highness Sheikh Nahyan bin Zayed Al Nahyan, and the significant expansion of the companys Scientific Advisory Board with world-renowned neuro-oncologists from Duke and NYU Langone Health. Heshmatpour brings over 25 years of senior executive and board-level experience in business development, operations, finance, and M&A. He is the founder, chairman, and managing director of AFH Holdings &Advisory, where he has led IPO transactions totaling over $1.5 billion, and private funding and M&A transactions exceeding $5 billion in aggregate value. Previously, Heshmatpour served as Chairman and CEO of Metrophone Telecommunications, which he founded in 1994. Under his leadership, Metrophone completed 17 acquisitions and grew annual revenues to over $100 million during a decade of sustained expansion. He has served on the board of the UCLA Anderson School of Management for more than 12 years, and is a board member of the Make-A-Wish Foundation for the Central Coast and Southern Central Valley of California. Annuncio • Oct 10
NeOnc Technologies Holdings, Inc. Expands NuroMENA Holdings Ltd. Board of Directors NeOnc Technologies Holdings, Inc. is expanding the NuroMENA Board of Directors, appointing key partners from Quazar Investment to drive regional governance and growth. To guide this new phase of growth, the NuroMENA board will be expanded to include new members: Waleed K. Al Ali, the CEO of Quazar Investment, and the Chairman of Quazar Investment. They will serve alongside current NuroMENA directors Amir Heshmatpour, Dr. Ishwar K. Puri and Bader Al Monawer, creating a formidable leadership team to oversee the company’s regional strategy. Annuncio • Oct 03
Neonc Technologies Holdings, Inc. Appoints David M. Ashley to Its Scientific Advisory Board NeOnc Technologies Holdings, Inc. announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. David M. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and Director of The Preston Robert Tisch Brain Tumor Center at Duke, positions he has held since 2018 after joining from Australia, where he trained and led major neuro-oncology programs. He practices adult and pediatric neuro-oncology and oversees one of North America’s largest dedicated brain tumor centers, integrating clinical care, translational research, and education. His scholarship spans CNS tumor biology, immuno-oncology, and clinical trials, and he has served as principal investigator on national and international studies that inform current practice. Dr. Ashley’s cross-continental career and leadership of a globally recognized brain-tumor center have earned him a strong international reputation for advancing patient-centered innovation in neuro-oncology. Annuncio • Oct 02
NeOnc Technologies Holdings, Inc. Appoints Dr. Alexandra M. Miller to Its Scientific Advisory Board NeOnc Technologies Holdings, Inc. announced the appointment of Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller is the Chief of the Neuro-oncology Program and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, where she specializes in treating patients with primary brain tumors. Alexandra M. Miller is a neurologist and neuro-oncologist who leads NYU Langone’s Perlmutter Cancer Center Neuro-Oncology Program as Chief of the Division of Neuro-Oncology and Co-Director of the Brain & Spine Tumor Center. Her clinical practice and research focus on primary brain tumors, especially malignant gliomas, where she guides multidisciplinary care and program strategy across a major NCI-designated cancer center. Dr. Miller holds clinical faculty appointments in Medicine and Neurology at NYU Grossman School of Medicine, reflecting her cross-disciplinary work at the interface of neurology, oncology, and clinical trials. Her leadership posts at a top academic center underscore her reputation and profile, significant invited talks, program development, and collaborative research networks in neuro-oncology. Annuncio • Sep 30
NeOnc Technologies Holdings, Inc. Appoints Dr. Henry S. Friedman to Scientific Advisory Board NeOnc Technologies Holdings, Inc. announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings. Henry S. Friedman, MD, Duke University: Henry S. Friedman is a senior neuro-oncologist at Duke and longtime leader at The Preston Robert Tisch Brain Tumor Center, where he serves as a deputy director and holds the James B. Powell, Jr. Distinguished Professorship in the School of Medicine. He cares for adult and pediatric patients at the Duke Cancer Center’s Brain Tumor Clinic and is an internationally renowned authority in neuro-oncology, with a publication record exceeding 500 peer-reviewed works and decades of national and international presentations. His work has spanned clinical trials and translational research across high-grade glioma, medulloblastoma, and ependymoma, helping to shape modern standards for difficult central nervous system (CNS) tumors. He has offered sustained leadership to one of the field’s best-known programs and ongoing engagement with collaborative, multi-center research efforts. Annuncio • Sep 11
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer NeOnc Technologies Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has authorized the Company to proceed with Phase IIa/IIb of its NEO212-01 clinical trial. The FDA's decision follows the successful completion of the Phase I dose-escalation study, which demonstrated that NEO212 could be safely administered at doses up to 810 mg daily on Days 1-5 of a 28-day cycle. Independent review of the recommended Phase II dose is ongoing, with patient enrollment expected to begin before the end of 2025. NEO212 is NeOnc's first oral chemical conjugated chemotherapy drug, uniquely combining Temozolomide (TMZ) - the current standard of care for glioblastoma and other brain cancers (marketed as Temodar®?) - with NEO100 (a proprietary form of perillyl alcohol (POH), which is owned and patented by NeOnc). This proprietary conjugation is designed to overcome the limitations of TMZ, including resistance and limited efficacy, by enhancing blood-brain barrier penetration and antitumor activity. NeOnc believes NEO212 has the potential to replace TMZ as the future standard of care for all brain cancers, representing a transformative leap forward in therapeutic options for patients facing glioblastoma, astrocytoma, and other aggressive CNS malignancies. Phase II Clinical Development Strategy: The NEO212-01 Phase II trial will expand patient enrollment across leading U.S. cancer centers, building on four currently approved and active trial sites: NextGen Oncology - Kumar Sankhala, MD; Northwest Medical Specialties (NWMS) - Jorge Chaves, MD; Oncology Physician's Network - Vu Phan, MD; University of Southern California (USC) - Frances Chow, MD. In anticipation of expanded Phase II enrollment, NeOnc is preparing activation at a broad network of premier cancer institutions, including: Baylor Scott & White; Beverly Hills Cancer Center - Cancer Specialists of North Florida; Cleveland Clinic - Duke University - Inova (Virginia) - New York University Langone - Providence St. John's * RecioMed (Florida) - Sutter Health - Tampa General Hospital - Vanderbilt University Medical Center - University of Texas Southwestern University of California, San Francisco. Annuncio • Aug 26
NeOnc Technologies Holdings, Inc. (NasdaqGM:NTHI) completed the acquisition of Artificial Intelligence, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri. NeOnc Technologies Holdings, Inc. (NasdaqGM:NTHI) signed a definitive agreement to acquire Artificial Intelligence, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri for $3.5 million on July 30, 2025. The purchase price consists of $0.5 million cash and $3 million in NeOnc common stock issued at $25 per share. As part of the transaction, NeOnc Technologies Holdings, Inc. appoints Dr. Ishwar K. Puri to its Board of Directors.
NeOnc Technologies Holdings, Inc. (NasdaqGM:NTHI) completed the acquisition of Artificial Intelligence, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri on August 25, 2025. Annuncio • Aug 25
NeOnc Technologies Holdings, Inc. Announces Resignation of Dr. Ming-Fu Chiang from the Board, Effective August 18, 2025 NeOnc Technologies Holdings, Inc. announced that on August 18, 2025, Dr. Ming-Fu Chiang notified the Board of Directors of the Company of his decision to resign from the Board, effective August 18, 2025. Mr. Chiang’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Dr. Chiang will continue serving on the Company’s science advisory board. Annuncio • Aug 15
NeOnc Technologies Holdings, Inc. announced delayed 10-Q filing On 08/14/2025, NeOnc Technologies Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Annuncio • Aug 07
NeOnc Technologies Holdings, Inc. Announces the Award of Two Competitive Nih Sttr (Small Business Technology Transfer) Grants Totaling $2.5 Million NeOnc Technologies Holdings, Inc. announced the award of two competitive NIH STTR (Small Business Technology Transfer) grants totaling $2.5 million. These non-dilutive funds will further advance development of the company’s proprietary therapeutic compound NEO212, which is currently completing its Phase 1 clinical trial. $400,000 Phase 1 STTR Grant (1R41CA27179-01A1): Supports preclinical feasibility studies of NEO212 in acute myelogenous leukemia (AML). Dr. Thomas Chen serves as NeOnc’s Principal Investigator (PI), with Dr. Axel H. Schönthal leading the academic research effort at USC’s Glioma Research Group. $2.1 Million Phase 2 STTR Grant (2R42CA246902-02): Focused on expanding NEO212’s clinical development into newly diagnosed gliomas, reinforcing the therapeutic’s broad oncologic potential. Dr. Chen is the PI for NeOnc, with Dr. Radu Minea leading the USC component. These prestigious NIH awards arrive as NeOnc approaches the end-of-Phase 1 milestone for NEO212, marking a pivotal point in the company’s path toward Phase 2 trial initiation and potential regulatory engagement. The STTR mechanism enables collaborative development between NeOnc and leading academic institutions, with each grant structured as 40% funding to NeOnc Technologies and 60% to its USC-based research collaborators. This funding builds on NeOnc’s growing clinical and translational momentum as the company continues to innovate across glioblastoma, leukemia, and other high-unmet-need indications. Annuncio • Jul 31
NeOnc Technologies Holdings, Inc. Appoints Ishwar K. Puri to Its Board of Directors NeOnc Technologies Holdings, Inc. announced appointment of Dr. Ishwar K. Puri to its Board of Directors. Dr. Puri currently serves as Senior Vice President of Research and Innovation at the University of Southern California (USC), where he oversees one of the nation’s most dynamic research portfolios. He is a Fellow of the AAAS, the Canadian Academy of Engineering (CAE), and the American Society of Mechanical Engineers (ASME), and is ranked among the top 0.4% of scholars worldwide across all fields by citation impact as per ScholarGPS. He has authored over 200 publications and has held prestigious academic and national leadership roles across the U.S. and Canada. Annuncio • Jul 30
NeOnc Technologies Holdings, Inc. announced that it expects to receive $50 million in funding from Quazar Investment NeOnc Technologies Holdings, Inc. announced that it has entered into a definitive agreement with Quazar Investment to issue 2,000,000 common shares at an issue price of $25 per share for gross proceeds of $50,000,000 on July 29, 2025. The transaction includes participation from lead investor, Quazar Investment. Annuncio • Jun 06
NeOnc Technologies Holdings, Inc. Appoints Josh Neman as Chief Clinical Officer NeOnc Technologies Holdings, Inc. announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational research, and academic medicine. Dr. Neman joins NeOnc Technologies Holdings Inc. (NeOnc) from the Keck School of Medicine at the University of Southern California (USC), where he serves as Associate Professor of Neurological Surgery and Physiology & Neuroscience, and Scientific Director of the USC Brain Tumor Center. At USC, he also leads the Cancer Biology and Genomics PhD Program and serves as Director of Cancer Research Training and Education Coordination at the USC Norris Comprehensive Cancer Center- a leading National Cancer Institute-designated cancer research hospital. A nationally recognized leader in neurooncological sciences and cancer neuroscience, Dr. Neman’s research has advanced the understanding of how brain microenvironments influence the progression of brain tumors and metastases. His pioneering studies on tumor-neuron interactions, GABAergic signaling in cancer, and mechanisms of leptomeningeal dissemination have helped shape new therapeutic paradigms for both adult and pediatric brain tumors. In his role as Chief Clinical Officer, Dr. Neman will lead NeOnc’s clinical development strategy, including investigator-initiated trials and precision oncology partnerships. He will also play a key role in expanding NeOnc’s research collaborations with academic institutions, regulatory agencies, and patient advocacy groups. Annuncio • Apr 14
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of Neo100-01 for Malignant Gliomas in September NeOnc Technologies Holdings, Inc. announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial's 25-patient enrollment target. This landmark trial, for which read-out data is expected in early 2026, investigates NEO100, a proprietary, highly purified version of perillyl alcohol, delivered intranasally, a non-invasive method designed to bypass the blood-brain barrier through the olfactory and trigeminal nerves. NEO100-01 is the first intranasal therapy of its kind evaluated in malignant gliomas, particularly targeting IDH1 mutant Grade III and IV astrocytomas. Grade IV gliomas are among the most aggressive and deadly forms of brain cancer. NEO100 has been granted both Orphan Drug Designation and Fast Track Status by the U.S. Food and Drug Administration (FDA), reinforcing its potential as a significant advancement in the treatment of malignant gliomas. Annuncio • Apr 10
NeOnc Technologies Holdings, Inc. Appoints Amir Heshmatpour as President NeOnc Technologies Holdings, Inc. announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company’s strategic and clinical initiatives. Heshmatpour brings over 25 years of senior executive and board-level experience in business development, operations, finance, and M&A. He is the founder, chairman, and managing director of AFH Holdings & Advisory, where he has led IPO transactions totaling over $1.5 billion, and private funding and M&A transactions exceeding $5 billion in aggregate value. Previously, Heshmatpour served as Chairman and CEO of Metrophone Telecommunications, which he founded in 1994. Under his leadership, Metrophone completed 17 acquisitions and grew annual revenues to over $100 million during a decade of sustained expansion. He has served on the board of the UCLA Anderson School of Management for more than 12 years, and is a board member of the Make-A-Wish Foundation for the Central Coast and Southern Central Valley of California. Annuncio • Apr 09
NeOnc Technologies Announces Near Completion of Phase I Enrollment for Neo212 Brain Cancer Therapy NeOnc Technologies Holdings, Inc. announced that its Phase I clinical trial of NEO212, a development-stage chemotherapy-conjugated therapeutic for brain cancer, is nearing full enrollment. The final cohort (Cohort 5) is expected to complete the study's dosing protocol, marking a major milestone in the drug's development timeline. NEO212 is a proprietary conjugation of temozolomide (TMZ--the current standard-of-care chemotherapy for malignant gliomas--and perillyl alcohol (POH), a naturally occurring compound with anti-cancer properties. While the use of TMZ alone has served as a frontline treatment for brain cancers for years, it suffers from key limitations such as rapid degradation in the bloodstream, bone marrow suppression due to toxic metabolites, and limited effectiveness in tumors with active MGMT DNA-repair enzyme expression. NEO212 is designed to address these concerns by creating a stable, orally bioavailable molecule that retains activity in both MGMT-positive and MGMT-negative gliomas. The NEO212 trial protocol includes five escalating cohorts (3 patients per cohort). Annuncio • Jun 13
Neonc Technologies Holdings, Inc. has withdrawn its IPO in the amount of $82.5 million. Neonc Technologies Holdings, Inc. has withdrawn its IPO in the amount of $82.5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 6,000,000
Price\Range: $11.25 to $13.75
Discount Per Security: $1.1
Transaction Features: Reserved Share Offering Board Change • Mar 29
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). CFO & Director Keithly Garnett is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. 
